{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:43:46Z","timestamp":1785908626379,"version":"3.56.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a clonal plasma cell malignancy with high heterogeneity and poor prognosis. Mitochondrial ribosomal protein L13 (MRPL13) has been linked to tumor progression, but its role in MM remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed seven datasets comprising 3,117 patient samples from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study (referred to as the TCGA_MMRF cohort) and the Gene Expression Omnibus (GEO) database to evaluate the association between MRPL13 expression and overall survival (OS). Event-free survival (EFS) analysis was performed in the GSE24080 cohort, and progression-free survival (PFS) analysis was conducted in the GSE136337 cohort. We further analyzed single-cell transcriptomic profiles of 74,986 cells from 24 MM patients to delineate the expression landscape of MRPL13 across distinct cellular populations and functional subclusters and to assess its relationship with the immune microenvironment. We performed functional assays involving siRNA-mediated MRPL13 silencing to investigate its effects on MM cell proliferation and cell-cycle progression\n                      <jats:italic>in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High MRPL13 expression was associated with adverse clinical features and poor survival and was identified as a potential independent prognostic factor. Single-cell analysis revealed enrichment in metabolically active malignant plasma cells and an immunosuppressive microenvironment. Silencing MRPL13 inhibited proliferation and induced G0\/G1 arrest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MRPL13 predicts poor prognosis and promotes MM progression through metabolic and immune regulation, supporting its potential as a prognostic biomarker and therapeutic target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1880529","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:44:56Z","timestamp":1785905096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic and biological significance of MRPL13 in multiple myeloma: evidence from multi-cohort, single-cell analyses"],"prefix":"10.3389","volume":"16","author":[{"given":"Wanyi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]},{"name":"The Second Clinical Medical College, Fujian Medical University","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjian","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]},{"name":"The Second Clinical Medical College, Fujian Medical University","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]},{"name":"The Second Clinical Medical College, Fujian Medical University","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoling","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Affiliated Hospital of Jiujiang University","place":["Jiujiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyin","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]},{"name":"The Second Clinical Medical College, Fujian Medical University","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zechuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]},{"name":"The Second Clinical Medical College, Fujian Medical University","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihuang","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]},{"name":"The Second Clinical Medical College, Fujian Medical University","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]},{"name":"The Second Clinical Medical College, Fujian Medical University","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]},{"name":"The Second Clinical Medical College, Fujian Medical University","place":["Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41420-024-01818-6","article-title":"Targeted immunotherapy: harnessing the immune system to battle multiple myeloma","volume":"10","author":"Xu","year":"2024","journal-title":"Cell Death Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","article-title":"Mitochondrial metabolism and cancer therapeutic innovation","volume":"10","author":"Du","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228879","article-title":"Abnormal expression of mitochondrial ribosomal proteins and their encoding genes with cell apoptosis and diseases","volume":"21","author":"Huang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s316428","article-title":"MRPL13 act as a novel therapeutic target and could promote cell proliferation in non-small cell lung cancer","volume":"13","author":"Jing","year":"2021","journal-title":"Cancer Manage Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m117.809012","article-title":"Lactate-mediated\u00a0mitoribosomal defects impair mitochondrial oxidative phosphorylation and promote\u00a0hepatoma cell invasiveness","volume":"292","author":"Lee","year":"2017","journal-title":"J Biol Chem"},{"key":"B9","volume-title":"MMRF Commpass Study (MMRF-COMMPASS, NCT01454297)","year":"2011"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1665","article-title":"The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models","volume":"28","author":"Shi","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v122.21.125.125","article-title":"Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma","volume":"28","author":"Heuck","year":"2014","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003323","article-title":"Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: a cohort study of patients in the Total Therapy clinical trials","volume":"17","author":"Danziger","year":"2020","journal-title":"PloS Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods (San Diego Calif)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.9.4350","article-title":"Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications","volume":"76","author":"Towbin","year":"1979","journal-title":"PNAS"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1182\/blood-2024-198300","article-title":"Single-cell RNA sequencing of CAR-T cell infusion products reveals \u2018viral mimicry\u2019 as potential resistance mechanism","volume":"144","author":"Liang","year":"2024"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03585-2","article-title":"Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome","volume":"73","author":"Cheng","year":"2024","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026455","article-title":"The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy","volume":"145","author":"Korst","year":"2025","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.jid.2022.03.033","article-title":"Prominent B-cell signature differentiates discoid from subacute cutaneous lupus erythematosus","volume":"142","author":"Lerman","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-22-1769","article-title":"Single-cell discovery and multiomic characterization of therapeutic targets in multiple myeloma","volume":"83","author":"Yao","year":"2023","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer J For Clin"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Institute"},{"key":"B25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nrc4006","article-title":"Immunotherapy: Engineering a strategy for multiple myeloma","volume":"15","author":"Razzak","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt297","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12929-023-00956-w","article-title":"Role of mitochondrial alterations in human cancer progression and cancer immunity","volume":"30","author":"Wang","year":"2023","journal-title":"J BioMed Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s296038","article-title":"MRPL13 promotes tumor cell proliferation, migration and EMT process in breast cancer through the PI3K-AKT-mTOR pathway","volume":"13","author":"Cai","year":"2021","journal-title":"Cancer Manage Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205104","article-title":"Multi-omics analysis of MRPL-13 as a tumor-promoting marker from pan-cancer to lung adenocarcinoma","volume":"15","author":"Zhong","year":"2023","journal-title":"Aging"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-1507","article-title":"BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma","volume":"26","author":"Boyle","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1880529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:45:03Z","timestamp":1785905103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1880529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1880529"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1880529","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1880529"}}